Clinical trials: Neuroepithelial Tumor
Adult Glioblastoma
Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma
Glioblastomas are extremely resistant to treatment, including radiotherapy and/or chemotherapy. Mitogen-activated protein kinase (MAPK) cascades are key signaling pathways involved in the regulation of normal cell proliferation…
- Trial name
- GLYRad (NCT02364206)
- Testing
- LY2228820, Temozolomide, radiotherapy
- Where
- 6 sites in France
- Volunteers
- 18 people
- Sponsor
- Centre Jean Perrin
Recurrent Glioblastoma, Brain Tumor
Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour
This is a Phase I, open-label, multi-centre study designed to assess the safety and tolerability of Cediranib in combination with lomustine in patients with primary recurrent malignant brain tumour.
- Trial name
- NCT00503204
- Testing
- Cediranib, Lomustine
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
Glioblastoma
Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma
For patients with glioblastoma,postoperative radiotherapy combined with concurrent and adjuvant temozolomide (Stupp regimen) has long been considered a standard treatment approach.The treatment outcomes, however, are still…
- Trial name
- NCT04157478
- Testing
- Anlotinib Hydrochloride, Radiation therapy, Temozolomide
- Where
- 7 sites in China
- Volunteers
- 464 people
- Sponsor
- People's Hospital of Guangxi Zhuang Autonomous Region
Neuroblastoma, Ganglioneuroblastoma
Induction Chemoimmunotherapy for Patients With High-risk Neuroblastoma
The modern strategy of therapy of high-risk neuroblastoma, stage 4, consists of three phases - induction, consolidation and post- consolidation.
- Trial name
- NCT06071897
- Testing
- monoclonal antibodies GD2
- Where
- Russia
- Volunteers
- 15 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy
In this research study the investigators want to learn more about the effects, both good and bad, when the study drug Ribociclib is given after radiation therapy.
- Conditions
- High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Bithalamic High Grade Glioma
- Trial name
- NCT02607124
- Testing
- Ribociclib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Neuroblastoma
Neuroblastoma Precision Trial
This proposal sets forth the platform for a Precision Medicine clinical trial through the New Approaches to Neuroblastoma Therapy (NANT) consortium.
- Trial name
- NCT02868268
- Testing
- Gene panel sequencing of tumor specimens
- Where
- 11 sites in United States
- Volunteers
- 93 people
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
Retinoblastoma, Retinal Neoplasm
Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma
Retinoblastoma is a childhood cancer which affects the retina of the eye. The retina is the light sensitive layer of tissue that lines the back of the eyeball; sends visual messages through the optic nerve to the brain.
- Trial name
- NCT00186888
- Testing
- Enucleation, Vincristine, Carboplatin, Focal Therapies
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- St. Jude Children's Research Hospital
Adult Brain Glioblastoma, Adult Gliosarcoma
EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma
This phase I/II trial studies the side effects and best dose of epidermal growth factor receptor bispecific antibody (EGFRBi)-armed autologous T cells and how well it works in treating patients with glioblastoma that have come…
- Conditions
- Adult Brain Glioblastoma, Adult Gliosarcoma, Recurrent Brain Neoplasm
- Trial name
- NCT02521090
- Testing
- EGFRBi-Armed Autologous T Cells, Laboratory Biomarker Analysis
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Glioblastoma
RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.
In prior trials of CMV RNA-pulsed dendritic cell vaccines, there has been a narrow window between surgery and initiation of chemoradiation to enroll patients and perform leukapheresis (to obtain cells needed to generate…
- Trial name
- NCT04963413
- Testing
- Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Florida
Brain Cancer, Glioblastoma Multiforme
Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
Phase I Objectives: -To determine the maximum tolerated dose (MTD) of vorinostat + erlotinib versus vorinostat + erlotinib + temozolomide in adult patients with recurrent glioblastoma multiforme (GBM) and anaplastic gliomas.
- Trial name
- NCT01110876
- Testing
- Vorinostat, Erlotinib, Temozolomide
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Brain and Central Nervous System Tumors
Epothilone ZK-219477 in Treating Patients With Recurrent Glioblastoma
RATIONALE: Drugs used in chemotherapy, such as epothilone ZK-219477, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00424060
- Testing
- sagopilone, fluorescence in situ hybridization, gene expression analysis
- Where
- Switzerland
- Volunteers
- 38 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
Targeted Pediatric High-Grade Glioma Therapy
The goal of this study is to perform genetic sequencing on brain tumors from children, adolescents, and young adult patients who have been newly diagnosed with a high-grade glioma.
- Conditions
- High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma
- Trial name
- NCT05839379
- Where
- 22 sites in United States, Australia and 5 more
- Volunteers
- 350 people
- Sponsor
- Nationwide Children's Hospital
CNS Tumor, Adult
Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma
RATIONALE : IMA 950 is multi tumour-associated peptides (TUMAPs) vaccine, these peptides have been identified on primary glioblastoma multiforme (GBM) cells.
- Trial name
- NCT01920191
- Testing
- IMA 950, Poly ICLC, Immunomonitoring
- Where
- Switzerland
- Volunteers
- 19 people
- Sponsor
- University Hospital, Geneva
Bone Marrow Suppression, Brain and Central Nervous System Tumors
Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Bone Marrow Suppression, Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ
- Trial name
- NCT00005796
- Testing
- filgrastim, gene therapy, lomustine
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Indiana University
Brain and Central Nervous System Tumors
Radiation Therapy Plus Hyperbaric Oxygen in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Hyperbaric oxygen may increase the effectiveness of radiation therapy.
- Trial name
- NCT00006460
- Testing
- hyperbaric oxygen, radiation therapy
- Where
- United States
- Sponsor
- Barrett Cancer Center
Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma
STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain
This phase I trial studies the side effects and best dose of STAT3 inhibitor WP1066 in treating patients with malignant glioma that has come back or melanoma that has spread to the brain and is growing, spreading, or getting…
- Conditions
- Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Recurrent Brain Neoplasm, Recurrent Glioblastoma
- Trial name
- NCT01904123
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, STAT3 Inhibitor WP1066
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
Meningioma, Glioblastoma
Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures
This pilot clinical study evaluates the safety and imaging performance of panitumumab-IRDye800 (pan800), a fluorescent, EGFR-targeted imaging agent - in patients undergoing neurosurgical resection of intracranial lesions.
- Conditions
- Meningioma, Glioblastoma, Acoustic Neuroma, Brain Cancer
- Trial name
- NCT07493447
- Testing
- Panitumumab-IRDye800
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Eben Rosenthal
Neoplastic Syndrome, Neuroblastoma
Studying Gene Expression in Samples From Younger Patients With Neuroblastoma
RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01553448
- Testing
- gene expression analysis, protein expression analysis, enzyme-linked immunosorbent assay
- Volunteers
- 75 people
- Sponsor
- Children's Oncology Group
Brain and Central Nervous System Tumors
Gene Therapy in Treating Patients With Primary Brain Tumors
RATIONALE: Inserting the gene for herpes virus into a person's cells may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy using antiviral drugs such as ganciclovir.
- Trial name
- NCT00002824
- Testing
- gene therapy, chemotherapy, ganciclovir
- Where
- United States
- Sponsor
- Abramson Cancer Center at Penn Medicine
Retinoblastoma
Deep Learning in Retinoblastoma Detection and Monitoring.
Retinoblastoma is the most common eye cancer of childhood. Eye-preserving therapies require routine monitoring of retinoblastoma regression and recurrence to guide corresponding treatment.
- Trial name
- NCT05308043
- Testing
- Deep learning algorism
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Beijing Tongren Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.